Bafna PharmaceuticalsNSE:BAFNAPH -2.00%60 Net Current Asset Value is ₹4.34 as of Mar. 2026, which is 100% below its 10-year median of 10.78. GuruFocus rates NSE:BAFNAPH with a GF Score™ of 60/100 and a GF Value™ of ₹92.04 (Significantly Overvalued). The stock has 9 warning signs investors should review. Among 613 Drug Manufacturers companies, Bafna Pharmaceuticals ranks worse than 95.27% on this metric.
In calculating the Net Current Asset Value (NCAV), Benjamin Graham means a company's current assets (such as cash, marketable securities, and inventories) minus its total liabilities (including preferred stock, minority interest, and long-term debt).
Bafna Pharmaceuticals's net current asset value per share for the quarter that ended in Mar. 2026 was ₹4.34.
The historical rank and industry rank for Bafna Pharmaceuticals's Net Current Asset Value or its related term are showing as below:
NSE:BAFNAPH'
s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 1.33 Med: 10.78 Max: 50.82
Current: 50.81
During the past 13 years, the highest Price-to-Net-Current-Asset-Value Ratio of Bafna Pharmaceuticals was 50.82. The lowest was 1.33. And the median was 10.78.
NSE:BAFNAPH's Price-to-Net-Current-Asset-Value is ranked worse than 95.27% of 613
companies
in the Drug Manufacturers industry
Industry Median: 5.71
vs NSE:BAFNAPH: 50.81
Bafna Pharmaceuticals (NSE:BAFNAPH) Net Current Asset Value Explanation
Benjamin Graham first discussed net current asset value (NCAV) in the 1934 edition of "Security Analysis", which he coauthored with David Dodd. In the book, (net) current asset value is defined as:" current assets alone, minus all liabilities and claims ahead of the issue."
The common definition of NCAV is: NCAV = current assets – [total liabilities + minority interest + preferred stock]
Net current assets exclude not only the intangible assets but also the fixed and miscellaneous assets. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.
One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Grahams strategy produced similar results.
Benjamin Graham looked for companies whose market values were less than two-thirds of their Net-Net Working Capital. They are collected under our Net-Net screener.
Bafna Pharmaceuticals Net Current Asset Value Related Terms
Bafna Pharmaceuticals Net Current Asset Value Historical Data
* Premium members only.
The historical data trend for Bafna Pharmaceuticals's Net Current Asset Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bafna Pharmaceuticals Net Current Asset Value Chart
NSE:BAFNAPH vs ZTS, UTHR: Net Current Asset Value Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Bafna Pharmaceuticals's Price-to-Net-Current-Asset-Value, along with its competitors' market caps and Price-to-Net-Current-Asset-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bafna Pharmaceuticals Price-to-Net-Current-Asset-Value vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Bafna Pharmaceuticals's Price-to-Net-Current-Asset-Value distribution charts can be found below:
* The bar in red indicates where Bafna Pharmaceuticals's Price-to-Net-Current-Asset-Value falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Net Current Asset Value of ₹4.34 mean?
Bafna Pharmaceuticals (NSE:BAFNAPH) has a Net Current Asset Value of ₹4.34 as of Mar. 2026. Ben Graham's net current asset value equals the per-share value of total current assets less total liabilities. View historical data on Bafna Pharmaceuticals and its competitors. This is 60% below median its historical median of 10.78. Over the past decade, Bafna Pharmaceuticals' Net Current Asset Value has ranged from 1.33 to 50.82. According to the industry distribution chart, Bafna Pharmaceuticals ranks #584 out of 613 companies in the Drug Manufacturers industry, placing it in the top 95.3%.
Is Bafna Pharmaceuticals' Net Current Asset Value too high?
Bafna Pharmaceuticals' current Net Current Asset Value of ₹4.34 is 60% below median its 10-year median of 10.78. Over the past 10 years, this metric has ranged from a low of 1.33 to a high of 50.82. Based on the distribution chart, Bafna Pharmaceuticals ranks #584 out of 613 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Bafna Pharmaceuticals has a GF Score™ of 60/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Bafna Pharmaceuticals' Net Current Asset Value compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Bafna Pharmaceuticals ranks #584 out of 613 companies for Net Current Asset Value. This places Bafna Pharmaceuticals in the lower half of its industry. The industry median Net Current Asset Value is 5.71. Historically, Bafna Pharmaceuticals' own Net Current Asset Value has ranged from 1.33 to 50.82 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Current Asset Value for a Drug Manufacturers company?
The median Net Current Asset Value among Drug Manufacturers companies is 5.71, based on 613 companies in the industry. Companies in the top quartile (top 25%) have a Net Current Asset Value significantly above this median, while those in the bottom quartile fall well below. However, Net Current Asset Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Current Asset Value mean?
A high Net Current Asset Value can signal that a stock is expensive relative to its fundamentals. Ben Graham's net current asset value equals the per-share value of total current assets less total liabilities. View historical data on Bafna Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median Net Current Asset Value is 5.71 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bafna Pharmaceuticals's current Net Current Asset Value is ₹4.34, which is 60% below median its own 10-year median of 10.78. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bafna Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Bafna Pharmaceuticals (NSE:BAFNAPH) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹92.04, compared to a current price of ₹216.45 — trading 135.2% above its estimated fair value. The current Net Current Asset Value is ₹4.34, which is 60% below median its 10-year median of 10.78. Bafna Pharmaceuticals' overall GF Score™ is 60/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Current Asset Value calculated?
Net Current Asset Value is calculated from a company's financial statements. For Bafna Pharmaceuticals (NSE:BAFNAPH), the current Net Current Asset Value is ₹4.34 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bafna Pharmaceuticals (NSE:BAFNAPH) Overvalued in 2026?
Based on GuruFocus' analysis, Bafna Pharmaceuticals stock appears to be overvalued.
The current stock price of ₹216.45 is trading 135.2% above its estimated GF Value™ of ₹92.04.
GuruFocus considers Bafna Pharmaceuticals to be Significantly Overvalued.
Key valuation signals for NSE:BAFNAPH:
Net Current Asset Value: ₹4.34 (60% below median its 10-year median of 10.78)
GF Value™: ₹92.04 vs. price of ₹216.45 (135.2% above fair value)
No single metric tells the full story. See the NSE:BAFNAPH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Bafna Pharmaceuticals Ltd is an Indian pharmaceutical company mainly offering Contract Research and Manufacturing (CRAMS), Technology Transfers, Formulation, and Analytical Development services. It is engaged in the business of manufacturing finished pharmaceutical formulations, specializing in non-betalactam solid oral dosage forms, besides other emerging and potential products and forms in various therapeutic areas such as cardiology, lifestyle and potent drugs, and pain management. The company delivers generic pharmaceutical products for the UK, Australia, the EU, and emerging markets. In addition, it has launched its own brands in Sri Lanka, the Philippines, Tanzania, and Nigeria, offering products for some high-demand therapies like diabetes, cardiovascular, and oncology.
60GF Score
Get the complete analysis for NSE:BAFNAPH
Net Current Asset Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:BAFNAPH has been successfully added to your 
